The genetic testing firm 23andMe has filed for bankruptcy, another twist in the story of a company that promised a pioneering approach to precision health. Now users are scrambling to delete their personal data, with the future ownership of the firm uncertain. To understand the highs and lows of 23andMe’s journey, Madeleine Finlay hears from the Guardian US tech reporter and editor Johana Bhuiyan, and from Timothy Caulfield, a professor of law at the University of Alberta, who has a special interest in health and biotechnology. Help support our independent journalism at theguardian.com/sciencepod